Atara Biotherapeutics, Inc.

ATRA

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Redmile Group EcoR1 Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Redmile GroupNEWFeb 17, 2026

Shares: 441,701Value: $8.0M

# Signal Note: Redmile Initiates ATRA Position Redmile's $8M entry into Atara suggests conviction in upcoming clinical/regulatory catalysts for the company's T-cell immunotherapy pipeline, most likely the ASTCT data readout expected in 1H 2024 for allogeneic CAR-T in relapsed/refractory lymphomas or the potential FDA decision timeline for tomivimab in CMV. Green's healthcare crossover expertise typically signals he sees either undervalued clinical probability or mispricing ahead of inflection events rather than speculative positioning.

EcoR1 CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ORIC2 funds IMNM2 funds NGNE2 funds NUVB2 funds ZYME2 funds ETON1 fund MNKD1 fund CGON

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: EcoR1 Capital Initiates ATRA Position** EcoR1's $10.4M entry into Atara signals conviction in its allogeneic CAR-T pipeline, particularly tabelecleucel for EBV+ post-transplant lymphoproliferative disorder (PTLD), which faces a competitive but underserved market with recent FDA approval (2023). The timing suggests positioning ahead of potential near-term catalysts: expanded label applications, clinical data readouts in other EBV-associated malignancies, or partnership developments that could de-risk the company's commercial execution.